IndraLab

Statements

Crizotinib inhibits KCNH2. 2 / 2

1 | 1

reach

"QTc prolongation has been observed in patients receiving crizotinib (Xalkori, 2011) and the clinical review (Pfizer I, 2011a) reported that crizotinib inhibits hERG at concentrations consistent with t[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"

23707608

➶

ctd

No evidence text available

23707608

INDRA sources:

Colored badges next to statement headings correspond to evidence counts from knowledge sources, as shown below. Badges to the left of the | separator correspond to curated knowledge base sources, and badges to the right of it correspond to machine reading systems.

IndraLab

Statements

Crizotinib inhibits KCNH2. 2 / 2

INDRA sources:

Databases

Reading